Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has successfully expanded its overseas market and is expected to see a performance turning point in the second half of the year [8] - The company's revenue for the first half of 2025 was 16.743 billion (down 18.45% year-on-year), with a net profit attributable to shareholders of 5.069 billion (down 32.96%) [8] - The international business revenue reached 8.332 billion (up 5.39%), accounting for 49.77% of total revenue, with significant growth in international diagnostic and chemiluminescence businesses [8] Financial Forecasts and Valuation - Revenue projections for 2025-2027 have been adjusted to 11.36 billion, 12.39 billion, and 14.41 billion respectively, with corresponding P/E ratios of 26, 24, and 21 times [8] - The company’s gross margin remains stable across various product lines, with in-vitro diagnostics at 59.50%, life information and support at 60.56%, and medical imaging at 65.07% [8] - The company’s earnings per share (EPS) for 2025 is projected at 9.37 yuan, with a slight decrease from previous estimates [1][8]